Replies to post #2027 on Axim Biotechnologies Inc (AXIM)

[TexasMarvL]

Outside of the FDA Cleared Dry Eye Disease #LateralFlowTests and #ImmunoPass all of AXIMs pipeline is long-term.

#AXIMBiotech acquired #SapphireBiotech in 2020.
#Sapphirebiotech has a ton of #cancer research, including a drug in the Pre-Clinical stages and multiple early-detection rapid-results point-of-care cancer tests being developed.

Personally, I think the best way to invest in AXIM is to focus on the long-term. Buy a small position, basically forget about it, and see what happens.

Frustration over waiting on the FDA is the biggest enemy in realizing a return on AXIM. Maybe the FDA cleared DED tests will provide cashflow and a short-term return to shareholders. Or maybe #ImmunoPass is approved in EU or by FDA.

Good luck to all.

[Devolution]

If I may, the best thing to do is to visit their website:

https://aximbiotech.com/

Click around. They are an R&D company focusing on ultimately bringing to market rapid, inexpensive, home-use tests that can be used by the general public as well as by medical professionals.

Right now they have the two DED tests going to market, hopefully with Immunopass to follow once they get their EUA, then after that should be a simple test for skin cancer, etc.

AXIM is on the precipice of moving from purely R&D to using all that R&D to generate revenues.

[janeyH]

life will go on, just w/out the expectation of a MAJOR BLOWOUT on the near term horizon.